Press Releases

Date	Title	PDF Version
Nov 16, 2016	Alexion Receives NASDAQ Notification Related to the Late Filing of Form 10-Q
Nov 11, 2016	New Long-Term Data Presented at AASLD Show Reduction in Liver Fibrosis and Cirrhosis in a Cohort of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) Treated with Kanuma® (sebelipase alfa)
Nov 09, 2016	Alexion Provides Update on Form 10-Q Filing
Nov 03, 2016	Researchers to Present New Phase 1/2 Data on ALXN1210 in Patients with PNH at ASH 2016 Annual Meeting
Oct 27, 2016	Alexion Initiates Simultaneous Registration Trials of ALXN1210 for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS)
Oct 27, 2016	Alexion Reports Third Quarter 2016 Results
Oct 19, 2016	FDA Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease (GVHD)
Oct 10, 2016	Alexion Pharmaceuticals to Report Third Quarter 2016 Results on Thursday, October 27, 2016
Oct 06, 2016	New Long-Term Data Presented at WCPGHAN 2016 Show Rapid and Sustained Improvements in Important Markers of Liver Injury and Lipid Abnormalities in Children and Adults with Lysosomal Acid Lipase Deficiency (LAL-D) Treated with Kanuma® (sebelipase alfa)
Sep 23, 2016	Alexion Employees Volunteer Together in Company's First Global Day of Service

Search